undefined undefined undefined

SGLT2 inhibitor treatment in patients with cardiac amyloidosis

Event: Heart Failure 2024

Topic: Pharmacotherapy

Session: Amyloid cardiomyopathy: epidemiology, diagnosis, prognostic and treatment

Access

Like

Left ventricular fibrosis influences the time to recovery in patients with arrhythmia-induced cardiomyopathy

Event: ESC Congress 2023

Topic: Late Gadolinium Enhancement

Session: CMR tissue characterisation: why it matters

Access

Like

Ventricular-arterial coupling and sacubitril/valsartan treatment in patients with heart failure and reduced ejection fraction

Event: Heart Failure 2023

Topic: Haemodynamics of Heart Failure

Session: Chronic heart failure - pathophysiology and mechanisms 3

Access

Like

Effects of Sacubitril/Valsartan on left ventricular pressure-volume relationship in heart failure

Event: ESC Congress 2022

Topic: Myocardial Disease

Session: Acute and chronic heart failure: echocardiographic characterisation

Access

Like

Cardiac magnetic resonance T1 mapping for the diagnosis of cardiac amyloidosis in patients with left ventricular hypertrophy

Event: Heart Failure 2022

Topic: Imaging

Session: Imaging in chronic heart failure

Access

Like

Native T1 mapping for differential diagnosis of left ventricular hypertrophy

Event: EuroCMR 2021

Topic: Myocardial Disease

Session: ePoster session

Access

Like

Left ventricular mechanical dispersion in flow-gradient patterns of severe aortic stenosis

Event: ESC Congress 2020

Topic: Tissue Doppler, Speckle Tracking and Strain Imaging

Session: Echocardiography ePosters

Access

Like

The non-steroidal mineralocorticoid receptor antagonist finerenone prevents structural cardiac remodeling

Event: ESC Congress 2019

Topic: Ventricular Remodelling

Session: Basic science heart failure

Access

Like

Long-term hemodynamic improvement after transcatheter repair of secondary mitral regurgitation

Event: EuroEcho-Imaging 2018

Topic: Valvular Heart Disease

Session: Echocardiography: Valve Disease

Access

Like

Predictors for clinical improvement after transcatheter mitral valve repair

Event: ESC Congress 2018

Topic: Intervention

Session: Best Posters in mitral regurgitation

Access

Like

undefined undefined undefined

Contributor content

SGLT2 inhibitor treatment in patients with cardiac amyloidosis

Left ventricular fibrosis influences the time to recovery in patients with arrhythmia-induced cardiomyopathy

Ventricular-arterial coupling and sacubitril/valsartan treatment in patients with heart failure and reduced ejection fraction

Effects of Sacubitril/Valsartan on left ventricular pressure-volume relationship in heart failure

Cardiac magnetic resonance T1 mapping for the diagnosis of cardiac amyloidosis in patients with left ventricular hypertrophy

Native T1 mapping for differential diagnosis of left ventricular hypertrophy

Left ventricular mechanical dispersion in flow-gradient patterns of severe aortic stenosis

The non-steroidal mineralocorticoid receptor antagonist finerenone prevents structural cardiac remodeling

Long-term hemodynamic improvement after transcatheter repair of secondary mitral regurgitation

Predictors for clinical improvement after transcatheter mitral valve repair

ESC 365 is supported by